Increased plasma conc & risk of myopathy w/ inhibitors of OATP1B1 & BCRP transporters. Increased exposure w/ PIs. Increased Cmax
& AUC w/ gemfibrozil. Increased risk of myopathy w/ gemfibrozil, fenofibrate, other fibrates & niacin. Increased AUC w/ ezetimibe in hypercholesterolaemic patients. Decreased plasma conc of approximately 50% w/ antacid susp containing Al & Mg hydroxide. Decreased AUC by 20% & Cmax
by 30% w/ erythromycin. Increased AUC w/ simeprevir, clopidogrel, lopinavir, eltrombopag, darunavir, tipranavir, dronedarone, itraconazole. Decreased AUC w/ baicalin. May either increase or decrease INR in patients taking vit K antagonists (eg, warfarin or another coumarin anticoagulant). Increased plasma levels of ethinyl estradiol & norgestrel. Increased exposure in patients known to have the c.521CC or c.421AA genotype.